TP53 and hepatobiliary neoplasm: Makower et al.315 led to a phase II clinical trial of oncolytic adenovirus ONYX-015(dl1520, CI-1042), which intervenes the p53 pathway in 19 patients with hepatobiliary tumors, in which 15 cases expressed p53 mutations, and 5 patients had GBCs.316 In this study, 16 patients responded to the viral product in intralesional treatment, while serious toxicities (>grade 2) were rarely observed.